Research programme: heat shock protein modulators - Reata Pharmaceuticals

Drug Profile

Research programme: heat shock protein modulators - Reata Pharmaceuticals

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Kansas
  • Developer Reata Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action HSP70 heat-shock protein modulators; HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies
  • Research Alzheimer's disease; Demyelinating disorders

Most Recent Events

  • 12 Feb 2016 Reata Pharmaceuticals plans a phase-I trial in healthy volunteers in USA (PO; Capsule) (NCT02666963)
  • 12 Oct 2015 Early research in Alzheimer's disease in USA (unspecified route)
  • 12 Oct 2015 Early research in Demyelinating disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top